Biocartis Group NV
XBRU:BCART
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.29
0.29
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Biocartis Group NV
Biocartis Group NV
Cash & Cash Equivalents
Biocartis Group NV
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biocartis Group NV
XBRU:BCART
|
Cash & Cash Equivalents
€24.9m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Nyxoah SA
XBRU:NYXH
|
Cash & Cash Equivalents
€21.6m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Ion Beam Applications SA
XBRU:IBAB
|
Cash & Cash Equivalents
€109.3m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Sequana Medical NV
XBRU:SEQUA
|
Cash & Cash Equivalents
€4.2m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
Biocartis Group NV
Glance View
Biocartis Group NV which engages in the development of oncology molecular diagnostic solutions. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 619 full-time employees. The company went IPO on 2015-04-27. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.
See Also
What is Biocartis Group NV's Cash & Cash Equivalents?
Cash & Cash Equivalents
24.9m
EUR
Based on the financial report for Jun 30, 2023, Biocartis Group NV's Cash & Cash Equivalents amounts to 24.9m EUR.
What is Biocartis Group NV's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-23%
Over the last year, the Cash & Cash Equivalents growth was 26%. The average annual Cash & Cash Equivalents growth rates for Biocartis Group NV have been -45% over the past three years , -23% over the past five years .
You don't have any saved screeners yet
